Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. The company targets therapeutic areas where current treatments leave room for improvements in efficacy, safety, and dosing… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Viridian Therapeutics, Inc.\DE does
In the company’s own words
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. The company targets therapeutic areas where current treatments leave room for improvements in efficacy, safety, and dosing convenience, with particular emphasis on autoimmune and rare disease indications.
The company's pipeline centers on three primary therapeutic areas. First, Viridian is developing therapies for thyroid eye disease (TED), a serious autoimmune disorder causing inflammation within the eye orbit that can result in bulging eyes, double vision, pain, and potential blindness. The company's lead program, veligrotug, is a humanized monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R) for intravenous administration. Veligrotug has completed two pivotal Phase 3 trials (THRIVE and THRIVE-2) in active and chronic TED patients, with positive topline data announced in September and December 2024 respectively. The company submitted a biologics license application to the FDA in October 2025, which received Priority Review with a target action date of June 30, 2026. Viridian is also developing elegrobart, a subcutaneous IGF-1R antibody with an extended half-life designed for at-home patient self-administration via auto-injector.
Second, Viridian is developing a portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which have potential applications across multiple autoimmune disorders. VRDN-006 is designed as a selective Fc fragment for subcutaneous self-administration, while VRDN-008 is a half-life extended bispecific FcRn inhibitor combining an Fc fragment with an albumin-binding domain.
Third, the company is developing a thyroid-stimulating hormone receptor (TSHR) inhibitor candidate for potential use in treating Graves' disease and TED, with an anticipated IND submission in the fourth quarter of 2026.
Viridian holds worldwide commercialization rights to veligrotug and elegrobart, excluding Japan and greater China. The company is building commercial infrastructure including sales, marketing, market access, and patient services functions to support anticipated product launches. More information is available at www.viridiantherapeutics.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1590750
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Viridian Therapeutics, Inc.\DE — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Viridian Therapeutics, Inc.\DE’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Viridian Therapeutics, Inc.\DE and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Viridian Therapeutics, Inc.\DE's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Viridian Therapeutics, Inc.\DE's last four quarterly filings that the numbers alone won't show?”